Literature DB >> 18276738

Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists.

P I Sidiropoulos1, G Hatemi, I-H Song, J Avouac, E Collantes, V Hamuryudan, M Herold, T K Kvien, H Mielants, J M Mendoza, I Olivieri, M Østergaard, L Schachna, J Sieper, D T Boumpas, M Dougados.   

Abstract

OBJECTIVE: Recommendations and/or guidelines represent a popular way of integrating evidence-based medicine into clinical practice. The 3E Initiatives is a multi-national effort to develop recommendations for the management of rheumatic diseases, which involves a large number of experts combined with practising rheumatologists addressing specific questions relevant to clinical practice.
METHODS: Ten countries participated in three rounds of discussions and votes concerning the management of AS. A set of nine questions was formulated in the domains of diagnosis, monitoring and treatment, after a Delphi procedure. A literature search in MedLine was conducted. Predefined outcome parameters for the domains of diagnosis, monitoring and treatment were assessed. The evidence to support each proposition was evaluated and scored. After discussion and votes, the final recommendations were presented using brief statements by each national group, following which the final international recommendations were formulated.
RESULTS: A total of 2699 papers were found and 467 were selected for analysis. Twelve key recommendations were developed: three in the domain of diagnosis addressing general diagnostic considerations, early AS diagnosis and general practitioners' referral recommendations; three concerning monitoring of AS disease activity, severity and prognosis; six concerning pharmacological treatment (except biologics): non-steroidal anti-inflammatory drugs/COX-II inhibitors, bisphosphonates and treatment of enthesitis. The compiled agreement among experts ranged from 72% to 93%.
CONCLUSION: Recommendations for the management of AS were developed using an evidence-based approach followed by expert/physician consensus with high level of agreement. Involvement of a larger and more representative group of rheumatologists may improve their dissemination and implementation in daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276738     DOI: 10.1093/rheumatology/kem348

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  24 in total

1.  [Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

2.  A 24-year-old man with suspected sacroiliitis.

Authors:  Shirley Chow; Nigil Haroon
Journal:  CMAJ       Date:  2014-12-22       Impact factor: 8.262

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; K-G Hermann; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

5.  Osteoporosis in ankylosing spondylitis.

Authors:  Marina Magrey; Muhammad Asim Khan
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

Review 6.  Epidemiology of spondyloarthritis: a review.

Authors:  Gunnstein Bakland; Hans C Nossent
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

Review 7.  Setting the research agenda for improving health care in musculoskeletal disorders.

Authors:  Rachelle Buchbinder; Chris Maher; Ian A Harris
Journal:  Nat Rev Rheumatol       Date:  2015-06-16       Impact factor: 20.543

8.  Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.

Authors:  Martin Rudwaleit; Pascal Claudepierre; Martina Kron; Sonja Kary; Robert Wong; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-03-15       Impact factor: 5.156

Review 9.  Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.

Authors:  Katherine F Croom; M Asif A Siddiqui
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

10.  American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip Van Den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-09-24       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.